Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Americans generally like wolves − except when we’re reminded of our politics - 2Al-Sharaa denies he called for 80% of Syrians to return from Germany
- 3State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
- 45 Eating routine Well disposed Snacks to Keep You Fulfilled
- 5Pick Your Favored kind of salad
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- Russia earning billions from Hormuz blockade, German trade body says
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- Soldiers seize power in Guinea-Bissau and detain the president
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Brilliant and Gleaming: Excellence and Skincare Practices
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
